Skip to main content

Advertisement

SpringerLink
Log in

Cholangiocarcinoma: Expanding the Spectrum of Risk Factors

  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Introduction

Cholangiocarcinoma (CCA) is an epithelial cancer originating from the bile ducts with features of cholangiocyte differentiation. The global incidence of this rare disease is on the rise, and it is the second most common primary hepatobiliary malignancy. We reviewed risk factors for cholangiocarcinoma development and also described potential screening strategies for this malignancy. We also report two cases in which CCA developed in patients without previously determined risk factors known for CCA.

Discussion

The first case is a patient with longstanding secondary sclerosing cholangitis (SSC), and the second is a patient with autoimmune hepatitis (AIH). These two cases may indicate a possible association between SSC and AIH with CCA, thus, expanding the spectrum of risk factors of CCA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med 1999;341:1368–78. doi:10.1056/NEJM199910283411807.

    Article  PubMed  Google Scholar 

  2. Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 2004;40:472–7. doi:10.1016/j.jhep.2003.11.030.

    Article  PubMed  Google Scholar 

  3. Mouzas IA, Dimoulios P, Vlachonikolis IG, Skordilis P, Zoras O, Kouroumalis E. Increasing incidence of cholangiocarcinoma in Crete 1992-2000. Anticancer Res 2002;22:3637–41.

    PubMed  Google Scholar 

  4. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002;51(Suppl. 6):VI1–VI9. doi:10.1136/gut.51.suppl_6.vi1.

    Article  PubMed  Google Scholar 

  5. Boris B, Gregory JG. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 2008;48(1):308–21. doi:10.1002/hep.22310.

    Article  CAS  Google Scholar 

  6. Welzel TM, McGlynn KA, Hsing AW, O’Brien TR, Pfeiffer RM. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra-and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst 2006;98:873–5.

    Article  PubMed  Google Scholar 

  7. Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004;99:523–6. doi:10.1111/j.1572-0241.2004.04067.x.

    Article  PubMed  Google Scholar 

  8. Jimeno A, Rubio-Viqueira B, Amador ML, Oppenheimer D, Bouraoud N, Kulesza P, et al. Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. Cancer Res 2005;65:3003–10.

    PubMed  CAS  Google Scholar 

  9. Wiedmann M, Feisthammel J, Bluthner T, Tannapfel A, Kamenz T, Kluge A, et al. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. Anticancer Drugs 2006;17:783–95. doi:10.1097/01.cad.0000217433.48870.37.

    Article  PubMed  CAS  Google Scholar 

  10. Zhang Z, Lai GH, Sirica AE. Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Hepatology 2004;39:1028–37. doi:10.1002/hep.20143.

    Article  PubMed  CAS  Google Scholar 

  11. Wu T, Leng J, Han C, Demetris AJ. The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells. Mol Cancer Ther 2004;3:299–307.

    PubMed  CAS  Google Scholar 

  12. Date K, Matsumoto K, Kuba K, Shimura H, Tanaka M, Nakamura T. Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor. Oncogene 1998;17:3045–54. doi:10.1038/sj.onc.1202231.

    Article  PubMed  CAS  Google Scholar 

  13. Sirica AE, Lai GH, Endo K, Zhang Z, Yoon BI. Cyclooxygenase-2 and ERBB-2 in cholangiocarcinoma: potential therapeutic targets. Semin Liver Dis 2002;22:303–13. doi:10.1055/s-2002-34507.

    Article  PubMed  CAS  Google Scholar 

  14. Olnes MJ, Erlich R. A review and update on cholangiocarcinoma. Oncology 2004;66:167–79. doi:10.1159/000077991.

    Article  PubMed  Google Scholar 

  15. LaRusso NF, Shneider BL, Black D, Gores GJ, James SP, Doo E, et al. Primary sclerosing cholangitis: summary of a workshop. Hepatology 2006;44:746–64. doi:10.1002/hep.21337.

    Article  PubMed  Google Scholar 

  16. Gossard AA, Angulo P, Lindor KD. Secondary sclerosing cholangitis: a comparison to primary sclerosing cholangitis. Am J Gastroenterol 2005;100:1330–33. doi:10.1111/j.1572-0241.2005.41526.x.

    Article  PubMed  Google Scholar 

  17. Edward L. Krawitt, Autoimmune Hepatitis. New Engl J Med 2006;354:54–66. doi:10.1056/NEJMra050408.

    Article  Google Scholar 

  18. Charatcharoenwitthaya P, Enders FB, Halling KC, Lindor KD. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 2008;48(4):1106–117. doi:10.1002/hep.22441.

    Article  PubMed  CAS  Google Scholar 

  19. Chen CY, Shiesh SC, Tsao HC, Lin XZ. The assessment of biliary CA 125, CA 19-9 and CEA in diagnosing cholangiocarcinoma- the influence of sampling time and hepatolithiasis. Hepatogastroenterology 2002;49:616–20.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Mayo Clinic, W19A, 200 First Street, SW, Rochester, MN, 55905, USA

    Diaa H. Elfaki, Andrea A. Gossard & Keith D. Lindor

Authors
  1. Diaa H. Elfaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrea A. Gossard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Keith D. Lindor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Keith D. Lindor.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Elfaki, D.H., Gossard, A.A. & Lindor, K.D. Cholangiocarcinoma: Expanding the Spectrum of Risk Factors. J Gastrointest Canc 39, 114–117 (2008). https://doi.org/10.1007/s12029-008-9040-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-008-9040-0

Keywords

Search

Navigation